Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$7.75 +2.3%	$7.66	$6.51 ▼ $13.27	$8.21M	1.62	93,842 shs	950 shs
GLMD Galmed Pharmaceuticals	$1.44 +0.7%	$1.39	$1.15 ▼ $23.80	$2.37M	0.49	1.30 million shs	179,493 shs
ORGS Orgenesis	$1.94 -0.5%	$2.25	$0.87 ▼ $10.80	$9.31M	0.72	9,322 shs	360 shs
SLXN Silexion Therapeutics	$1.02 +6.3%	$0.93	$0.58 ▼ $41.85	$8.87M	0.06	5.15 million shs	1.05 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	0.00%	-6.40%	-3.18%	-6.00%	-9.94%
GLMD Galmed Pharmaceuticals	0.00%	+3.60%	+15.20%	-25.77%	-67.58%
ORGS Orgenesis	0.00%	+2.11%	-21.77%	-48.40%	+193,999,900.00%
SLXN Silexion Therapeutics	0.00%	-1.92%	+2.00%	-2.86%	+101,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.7449 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.8	0.0
GLMD Galmed Pharmaceuticals	1.4985 of 5 stars	0.0	4.0	0.0	0.0	2.8	2.5	0.6
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	287.35% Upside
GLMD Galmed Pharmaceuticals	2.00	Hold	N/A	N/A
ORGS Orgenesis	0.00	N/A	N/A	N/A
SLXN Silexion Therapeutics	3.00	Buy	$5.00	390.20% Upside

Current Analyst Ratings Breakdown

Latest GLMD, ORGS, SLXN, and ADXN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/4/2025	GLMD Galmed Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
3/20/2025	SLXN Silexion Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $5.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$404.10K	20.32	N/A	N/A	$1.20 per share	6.45
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$33.02 per share	N/A
ORGS Orgenesis	$662K	14.06	N/A	N/A	($6.58) per share	-0.29
SLXN Silexion Therapeutics	N/A	N/A	$0.70 per share	1.46	($6.63) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$11.76M	-$0.34	N/A	∞	N/A	850.30%	-112.43%	-77.95%	6/9/2025 (Estimated)
GLMD Galmed Pharmaceuticals	-$6.91M	-$16.66	N/A	∞	N/A	N/A	-28.75%	-24.98%	N/A
ORGS Orgenesis	-$55.36M	N/A	0.00	∞	N/A	-3,827.81%	N/A	-130.18%	8/6/2025 (Estimated)
SLXN Silexion Therapeutics	$260K	N/A	0.00	∞	N/A	N/A	N/A	-249.43%	6/17/2025 (Estimated)

Latest GLMD, ORGS, SLXN, and ADXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/9/2025	Q1 2025	ADXN Addex Therapeutics	-$1.4197	N/A	N/A	N/A	N/A	N/A
5/22/2025	Q1 2025	GLMD Galmed Pharmaceuticals	N/A	-$0.62	N/A	-$0.62	N/A	N/A
5/13/2025	N/A	SLXN Silexion Therapeutics	N/A	-$0.26	N/A	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	4.59	4.59
GLMD Galmed Pharmaceuticals	N/A	7.03	7.03
ORGS Orgenesis	N/A	0.07	0.07
SLXN Silexion Therapeutics	N/A	0.85	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
GLMD Galmed Pharmaceuticals	76.14%
ORGS Orgenesis	22.56%
SLXN Silexion Therapeutics	10.95%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
GLMD Galmed Pharmaceuticals	19.80%
ORGS Orgenesis	5.66%
SLXN Silexion Therapeutics	33.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
GLMD Galmed Pharmaceuticals	20	1.65 million	516,000	Not Optionable
ORGS Orgenesis	150	4.80 million	4.53 million	No Data
SLXN Silexion Therapeutics	N/A	8.69 million	1.07 million	N/A

GLMD, ORGS, SLXN, and ADXN Headlines

Recent News About These Companies

Silexion Therapeutics announces preclinical results on SIL204

May 30 at 8:50 PM | finance.yahoo.com

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

May 30 at 3:52 AM | msn.com

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

May 29, 2025 | finance.yahoo.com

Critical Analysis: BioNTech (NASDAQ:BNTX) versus Silexion Therapeutics (NASDAQ:SLXN)

May 26, 2025 | americanbankingnews.com

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers

May 23, 2025 | nasdaq.com

Silexion Therapeutics Receives Nasdaq Delisting Notice

May 23, 2025 | tipranks.com

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025 | globenewswire.com

Silexion Therapeutics Corporation Registered Shs

May 22, 2025 | markets.businessinsider.com

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

May 21, 2025 | finance.yahoo.com

Silexion Therapeutics Completes Preclinical Study on SIL204 for Expanded KRAS-Driven Cancer Therapies

May 21, 2025 | quiverquant.com

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025 | globenewswire.com

Silexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | finanznachrichten.de

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

Silexion Therapeutics enters collaboration with Catalent

April 25, 2025 | markets.businessinsider.com

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers

April 23, 2025 | quiverquant.com

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

April 23, 2025 | globenewswire.com

Silexion Therapeutics announces expanded development plan for SIL204

March 28, 2025 | markets.businessinsider.com

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

March 28, 2025 | globenewswire.com

Silexion announces completion of expanded development plan for SIL204

March 21, 2025 | markets.businessinsider.com

Silexion Therapeutics price target lowered to $5 from $9 at Maxim

March 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD, ORGS, SLXN, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$7.74 +0.18 (+2.31%)

Closing price 05/30/2025 03:56 PM Eastern

Extended Trading

$8.02 +0.27 (+3.55%)

As of 07:56 AM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Galmed Pharmaceuticals NASDAQ:GLMD

$1.44 +0.01 (+0.70%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.42 -0.01 (-1.04%)

As of 08:35 AM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Orgenesis NASDAQ:ORGS

$1.94 -0.01 (-0.51%)

As of 05/30/2025 10:30 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Silexion Therapeutics NASDAQ:SLXN

$1.02 +0.06 (+6.25%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.89 -0.13 (-12.84%)

As of 08:38 AM Eastern

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time